Facilities & Capacity

TFF boosts capacity for drug solubility tech

TFF Pharmaceuticals has leased a plant in Austin, Texas to expand development of its thin film freezing technology, which it says could increase the bioavailability of large molecule drugs. The expansion, of which is self-funded, but no specific financial details have been disclosed, sees TFF lease a 3,500 square-foot research and development plant located in Austin, Texas. “We decided to expand our facilities now to meet the current demand and increased interest in our technology. The TFF business model is…

Naobios completes manufacturing of FluGen’s intranasal flu vaccine candidate

Naobios has completed the production of a clinical batch of influenza vaccine candidate M2SR, allowing FluGen to begin clinical trials in the US.   FluGen and contract development manufacturing organization (CDMO) Naobios have partnered on the process development of a platform for FluGen’s M2SR vaccine candidate since 2019 and have now reached a key milestone in the collaboration, which will lead to the start of a clinical trial in the US this month.   M2SR is a live, single-replication, supra-seasonal, intranasal flu vaccine.…

Cytiva bolsters resin operations outside of Sweden with Michigan plant buy

Cytiva has invested in additional resins production operations outside of Sweden for the first time through the acquisition of a facility from BASF in Muskegon, Michigan. While specific financial details of the acquisition remain undisclosed, Cytiva has acquired the Muskegon plant from German multinational chemical company BASF and said the chromatography resins facility is part of its $1.5 billion capacity expansion investment announced in July 2021. Cytiva plans to make the site into a 168,000 square-foot biomanufacturing center, which includes multiple…

Avid opens viral vector facility, looks to FY23 to fill GMP capacity

Avid Bioservices has completed the first phase of its journey into cell and gene therapies, opening analytical and process development capabilities in California. In October 2021, biologics contract development and manufacturing organization (CDMO) Avid announced plans to move into the cell and gene therapy space through the construction of a 53,000 square-foot viral vector development and GMP manufacturing facility at a cost of between $65 and $75 million. After eight months and with help from engineering and construction firm CRB,…

Wacker breaks ground on $102m mRNA site in Germany

Once the expansion is complete the manufacturing capacity in Halle, Germany will be more than tripled, says Wacker. The expansion, which sees contract development manufacturing organization (CDMO) Wacker invest over $102 million, will consist of four floors connected to an existing building. In addition to the four messenger RNA (mRNA) production lines, the building will also include quality control laboratories, storage areas, and office space. According to Wacker, once operational the plant will produce mRNA coronavirus vaccines. In April the…

Albany College of Pharmacy to set up regional pharma services hub

The Albany College of Pharmacy and Health Sciences (ACPHS) says a newly acquired medical and life sciences facility will allow it to create a hub for contract services. The facility – which is adjacent to ACPHS’ campus in Albany, New York – is a 154,000 square-foot building that is “uniquely designed for life science research” the college said. It is equipped with biosafety level (BSL) 2 and BSL-3 research labs and will be home to ACPHS’s Center for Biopharmaceutical Education…

Lonza expands Stein site again with commercial fill-finish plant

Lonza will invest $521 million to construct a commercial large-scale fill-finish facility at its site in Stein, Switzerland. According to the Swiss contract development manufacturing organization (CDMO) the facility will support  customers across their entire product life cycle. The firm dubbed the facility located on the same campus as Lonza’s existing plant as “flexible” and said that the location will enable the company to make use of existing capabilities, talent, and infrastructure. “There is significant market demand for commercial drug…

Fujifilm: Latest $1.6bn spend to help quadruple CDMO’s mammalian capacity

Another $1bn+ investment boost, this time at sites in Denmark and Texas, will push Fujifilm Diosynth Biotechnologies into the top tier of CDMOs based on cell culture capacity. The $1.6 billion will be used to expand cell culture manufacturing capabilities at contract development and manufacturing organization (CDMO) Fujifilm’s Hillerød facility in Denmark and across the Atlantic at its single-use campus in College Station, Texas. “Currently, the market for antibody drugs is expected to grow at an annual rate of over…

CDMO plant roundups: News from CRL, Batavia, OrganaBio

Charles River opens a plasmid DNA plant in the UK, Batavia Biosciences is building a commercial vaccine facility in the Netherlands, and OrganaBio’s cell therapy manufacturing site in Florida is now up and running. Welcome to our CDMO roundup. First up this week is Charles River Laboratories (CRL), which – fresh from bagging contracts with Ziphius Vaccines and ASC Therapeutics – has opened its High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park in Cheshire, United…

AstraZeneca pumps $69m into Ireland drug substance capabilities

The investment will expand drug substance production capabilities at facilities in Blanchardstown and Athlone run by AstraZeneca subsidiary Alexion. Having acquired Alexion in June 2021 (six months after the $39 billion deal was announced), AstraZeneca pledged last week to expand its manufacturing footprint at its Irish facilities in College Park, Blanchardstown and Monksland Industrial Park, Athlone. The €65 million ($69 million) will be split across three investments, a spokesperson from the firm told this publication, with equipment and warehouse facilities…